It was reported on Thursday that United States-based BioMarin has named Maykin Ho, PhD, as its new director.
Dr Ho has over 30 years of experience in the healthcare and finance industries. She is serving on the boards of Agios Pharmaceuticals Inc, FibroGen Inc, Grail Inc, Parexel, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. She is a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. She has served in Goldman Sachs Group, DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company.
Jean-Jacques Bienaime, chairman and CEO at BioMarin, said, 'We are thrilled to welcome Maykin to BioMarin's board of directors. She brings a breadth and depth of experience in the healthcare industry and finance to an already exceptional board. Maykin brings an important perspective to support BioMarin's growth trajectory as we strive to address the unmet medical needs of people affected by rare genetic diseases and deliver scientific breakthroughs.'
ViiV Healthcare Gains FDA Approval of Cabenuva as long-Acting Regimen for HIV Treatment
US FDA Approves Cabenuva as Long-Acting Regimen for the Treatment of HIV
ViiV Healthcare wins FDA approval for HIV treatment Cabenuva
Incyte granted FDA priority review for retifanlimab BLA for SCAC
European Commission Authorises the First Complete Long-Acting Injectable HIV Treatment in Europe
Australian government stops development of local COVID-19 vaccine due to false HIV positives